Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $22.00

Vir Biotechnology (NASDAQ:VIR) had its target price hoisted by HC Wainwright from $20.00 to $22.00 in a research report sent to investors on Wednesday morning, Marketbeat reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Vir Biotechnology’s FY2028 earnings at ($1.71) EPS, FY2029 earnings at ($1.26) EPS and FY2030 earnings at ($0.29) EPS.

A number of other research firms have also recently weighed in on VIR. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Morgan Stanley set a $25.00 price objective on Vir Biotechnology in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Friday, October 2nd. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Vir Biotechnology presently has an average rating of “Moderate Buy” and a consensus target price of $21.86.

Vir Biotechnology Trading Up 5.2%

VIR opened at $11.70 on Wednesday. The company has a market cap of $1.98 billion, a P/E ratio of -6.29 and a beta of 1.59. The company’s 50 day moving average is $10.47 and its 200-day moving average is $9.79. Vir Biotechnology has a 1-year low of $4.82 and a 1-year high of $12.00.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14. The company had revenue of $238.95 million for the quarter, compared to analyst estimates of $135.88 million. Vir Biotechnology’s revenue for the quarter was up 19582.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.80) earnings per share. On average, equities analysts forecast that Vir Biotechnology will post -1.84 EPS for the current year.

Hedge Funds Weigh In On Vir Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fiduciary Financial Advisors acquired a new position in shares of Vir Biotechnology during the second quarter worth $29,000. Caxton Associates LLP acquired a new stake in Vir Biotechnology in the first quarter valued at $112,000. Amundi increased its holdings in Vir Biotechnology by 52.8% in the first quarter. Amundi now owns 15,315 shares of the company’s stock valued at $137,000 after purchasing an additional 5,294 shares during the period. Royal Bank of Canada increased its holdings in Vir Biotechnology by 223.1% in the first quarter. Royal Bank of Canada now owns 15,355 shares of the company’s stock valued at $138,000 after purchasing an additional 10,603 shares during the period. Finally, Maryland State Retirement & Pension System raised its position in Vir Biotechnology by 19.8% during the 1st quarter. Maryland State Retirement & Pension System now owns 16,163 shares of the company’s stock worth $145,000 after purchasing an additional 2,668 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Key Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: The FDA granted Fast Track designation to VIR-5500, Vir’s PSMA-targeted Pro-XTEN® dual-masked T-cell engager being developed with Astellas Pharma for prostate cancer. Fast Track status may facilitate more frequent FDA interaction and potentially expedite the review process, strengthening the program’s development and commercial prospects. FDA Fast Track designation for VIR-5500
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $22 price target, implying substantial potential upside from recent trading levels. The firm raised its FY2030 EPS forecast modestly, to a loss of $0.29 per share from a loss of $0.34, suggesting improved longer-term expectations. HC Wainwright forecast for Vir Biotechnology
• Neutral Sentiment: Vir appointed David Liu as executive vice president and chief medical officer, effective October 12, 2026. The leadership addition could support clinical development, but the announcement does not immediately change the company’s financial outlook. David Liu appointed chief medical officer
• Neutral Sentiment: Investors are also watching upcoming SOLSTICE Phase 2 hepatitis D data, which could materially influence Vir’s investment narrative when released. No clinical results were reported in the article. SOLSTICE Phase 2 data outlook
• Negative Sentiment: HC Wainwright slightly lowered its FY2028 and FY2029 EPS forecasts, to losses of $1.71 and $1.26 per share, respectively, indicating continued expected losses and some pressure on near-term estimates.
• Negative Sentiment: Zacks Research downgraded Vir Biotechnology from “Hold” to “Strong Sell,” creating a notable counterweight to HC Wainwright’s bullish view. Zacks rating downgrade

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing treatments and preventive therapies for serious infectious diseases. The company uses immunologic insights, antibody technology, cellular approaches and other scientific platforms to address diseases in which the immune system plays a central role.

Vir’s research and development programs have included therapies for chronic hepatitis B, influenza, human immunodeficiency virus (HIV) and COVID-19. Its pipeline has included investigational antibody and immunomodulatory candidates such as tobevibart and elebsiran for hepatitis B, as well as programs designed to prevent or treat other viral infections.